PITAVASTATIN CALCIUM- pitavastatin tablet, film coated Mylan Pharmaceuticals Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PITAVASTATIN TABLETS safely and effectively. See full prescribing information for PITAVASTATIN TABLETS.

PITAVASTATIN tablets, for oral use Initial U.S. Approval: 2009

RECENT MAJOR CHANGES
Contraindications, Pregnancy and Lactation (4) Removed 11/2022 Warnings and Precautions, Immune-Mediated Necrotizing Myopathy (5.2) 11/2022
INDICATIONS AND USAGE
Pitavastatin tablets are a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: (1)
 Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
DOSAGE AND ADMINISTRATION
 Take orally once daily with or without food at the same time each day. (2.1) For patients requiring a high-intensity statin or are unable to achieve their LDL-C goal receiving pitavastatin tablets 4 mg daily, prescribe alternative LDL-C-lowering treatment. (2.1) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiation of pitavastatin tablets, and adjust the dosage if necessary. (2.1) Recommended dosage is 2 mg to 4 mg once daily. Maximum recommended dosage is 4 mg once daily. (2.2) Recommended starting dosage for patients with moderate and severe renal impairment and end-stage renal disease on hemodialysis is 1 mg once daily. Maximum recommended dosage is 2 mg once daily. (2.3) See full prescribing information for pitavastatin tablets dosage modifications due to drug interactions. (2.4)
Tablets: 1 mg, 2 mg, and 4 mg (3)
CONTRAINDICATIONS
 Cyclosporine (4, 7) Active liver failure or decompensated cirrhosis (4, 5.3) Hypersensitivity to pitavastatin or any excipients in pitavastatin tablets (4)
WARNINGS AND PRECAUTIONS
 Myopathy and Rhabdomyolysis: Risk factors include age 65 or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher pitavastatin tablets dosage. Discontinue pitavastatin tablets if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue pitavastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pitavastatin tablets dosage.

- Instruct patients to promptly report unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever. (5.1, 7, 8.5, 8.6)
- *Immune-Mediated Necrotizing Myopathy (IMNM):* Rare reports of IMNM, an autoimmune myopathy, have been reported. Discontinue pitavastatin tablets if IMNM is suspected. (5.2)
- *Hepatic Dysfunction:* Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or

hyperbilirubinemia or jaundice occurs, promptly discontinue pitavastatin tablets. (5.3)

The most frequent adverse reactions (rate $\geq 2\%$) were myalgia, constipation, diarrhea, back pain, and pain in extremity. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full prescribing information for details regarding concomitant use of pitavastatin tablets with other drugs that increase the risk of myopathy and rhabdomyolysis. (2.4, 7) USE IN SPECIFIC POPULATIONS

- Pregnancy: May cause fetal harm. (8.1)
- Lactation: Breastfeeding not recommended during treatment with pitavastatin tablets. (8.2)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 2/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Dosage and Administration Information
- 2.2 Recommended Dosage for Adults and Pediatric Patients Aged 8 Years and Older
- 2.3 Recommended Dosage in Patients with Renal Impairment
- 2.4 Dosage Modifications Due to Drug Interactions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Myopathy and Rhabdomyolysis
- 5.2 Immune-Mediated Necrotizing Myopathy
- 5.3 Hepatic Dysfunction
- 5.4 Increases in HbA1c and Fasting Serum Glucose Levels

6 ADVERSE REACTIONS

- 6.1 Clinical Studies Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:

- Adults with primary hyperlipidemia.
- Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosage and Administration Information

- Take pitavastatin tablets orally once daily with or without food at the same time each day.
- For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pitavastatin tablets 4 mg daily, prescribe alternative LDL-C-lowering treatment.
- Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating pitavastatin tablets, and adjust the dosage if necessary.

2.2 Recommended Dosage for Adults and Pediatric Patients Aged 8 Years and Older

- The recommended dosage range of pitavastatin tablets is 2 mg to 4 mg daily.
- The maximum recommended dosage is pitavastatin tablets 4 mg once daily.

2.3 Recommended Dosage in Patients with Renal Impairment

- The recommended starting dosage for patients with moderate and severe renal impairment (estimated glomerular filtration rate 30–59 mL/minute/1.73 m² and 15– 29 mL/minute/1.73 m², respectively) and patients with end-stage renal disease receiving hemodialysis is pitavastatin tablets 1 mg once daily. The maximum recommended dose for these patients is pitavastatin tablets 2 mg once daily [see Use in Specific Populations (8.5)].
- There are no dosage adjustment recommendations for patients with mild renal impairment.

2.4 Dosage Modifications Due to Drug Interactions

- In patients taking erythromycin, do not exceed pitavastatin tablets 1 mg once daily [see Drug Interactions (7)].
- In patients taking rifampin, do not exceed pitavastatin tablets 2 mg once daily [see Drug Interactions (7)].

3 DOSAGE FORMS AND STRENGTHS

Pitavastatin Tablets are available containing 1.045 mg, 2.090 mg or 4.180 mg of pitavastatin calcium equivalent to 1 mg, 2 mg or 4 mg of pitavastatin, respectively.

- The 1 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **PU1** on the other side.
- The 2 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **PU2** on the other side.
- The 4 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **PU4** on the other side.

4 CONTRAINDICATIONS

Pitavastatin tablets are contraindicated in the following conditions:

- Concomitant use of cyclosporine [see Drug Interactions (7)].
- Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].
- Hypersensitivity to pitavastatin or any excipients in pitavastatin tablets. Hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin tablets [see Adverse Reactions (6)].

5 WARNINGS AND PRECAUTIONS

5.1 Myopathy and Rhabdomyolysis

Pitavastatin tablets may cause myopathy (muscle pain, tenderness, or weakness associated with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including pitavastatin tablets.

Risk Factors for Myopathy

Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use of certain drugs (including other lipid-lowering therapies), and higher pitavastatin tablets dosage [see Dosage and Administration (2.2), Drug Interactions (7), and Use in Specific Populations (8.5, 8.6)]. Dosages of pitavastatin tablets greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. The maximum recommended dose of pitavastatin tablets is 4 mg once daily.

Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis

Pitavastatin tablets are contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil [see Contraindications (4) and Drug Interactions (7)]. There are pitavastatin tablets dosage restrictions for patients taking erythromycin or rifampin [see Dosage and Administration (2.4)]. The following drugs when used concomitantly with pitavastatin tablets may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (> 1 grams/day), fibrates, and colchicine [see Drug Interactions (7)].

Discontinue pitavastatin tablets if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if pitavastatin tablets are discontinued. Temporarily discontinue pitavastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pitavastatin tablets dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

5.2 Immune-Mediated Necrotizing Myopathy

There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue pitavastatin tablets if IMNM is suspected.

5.3 Hepatic Dysfunction

Increases in serum transaminases have been reported with pitavastatin tablets [see Adverse Reactions (6)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including pitavastatin tablets.

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.

Consider liver enzyme testing before the initiation of pitavastatin tablets and when clinically indicated thereafter. Pitavastatin tablets are contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue pitavastatin tablets.

5.4 Increases in HbA1c and Fasting Serum Glucose Levels

Increases in HbA1c and fasting serum glucose levels have been reported with statins, including pitavastatin tablets. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in other sections of the labeling:

- Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.1)]
- Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions (5.2)]
- Hepatic Dysfunction [see Warnings and Precautions (5.3)]
- Increases in HbA1c and Fasting Serum Glucose Levels [see Warnings and Precautions (5.4)]

6.1 Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of one drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Adverse Reactions in Adults with Primary Hyperlipidemia

In 10 controlled clinical studies and 4 subsequent open-label extension studies, 3,291 adult patients with primary hyperlipidemia were administered pitavastatin tablets 1 mg to 4 mg daily. The mean continuous exposure of pitavastatin (1 mg to 4 mg) was 36.7 weeks (median 51.1 weeks). The mean age of the patients was 60.9 years (range; 18 years-89 years) and 52% were females. Approximately 93% of the patients were White, 7% were Asian/Indian, 0.2% were African American and 0.3% were Hispanic and other.

In controlled clinical studies and their open-label extensions, 3.9% (1 mg), 3.3% (2 mg), and 3.7% (4 mg) of pitavastatin tablets-treated patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: elevated creatine phosphokinase (0.6% on 4 mg) and myalgia (0.5% on 4 mg).

Adverse reactions reported in $\geq 2\%$ of patients in controlled clinical studies and at a rate greater than or equal to placebo are shown in Table 1. These studies had treatment duration of up to 12 weeks.

Adverse Reactions	Placebo (n = 208) %	Pitavastatin Tablets 1 mg (n = 309) %	Pitavastatin Tablets 2 mg (n = 951) %	Pitavastatin Tablets 4 mg (n = 1540) %
Myalgia	1.4	1.9	2.8	3.1
Constipation	1.9	3.6	1.5	2.2
Diarrhea	1.9	2.6	1.5	1.9
Back pain	2.9	3.9	1.8	1.4
Pain in extremity	1.9	2.3	0.6	0.9

Table 1. Adverse Reactions (≥ 2% and ≥ placebo) in Adults with Primary Hyperlipidemia in Studies up to 12 Weeks

Other adverse reactions reported from clinical studies were arthralgia, headache, influenza, and nasopharyngitis.

Hypersensitivity reactions including rash, pruritus, and urticaria have been reported with pitavastatin tablets.

The following laboratory abnormalities have been reported: elevated creatine phosphokinase, transaminases, alkaline phosphatase, bilirubin, and glucose.

Adverse Reactions in Adult HIV-Infected Patients with Dyslipidemia

In a double-blind, randomized, controlled, 52-week trial, 252 HIV-infected patients with dyslipidemia were treated with either pitavastatin tablets 4 mg once daily (n = 126) or another statin (n = 126). All patients were taking antiretroviral therapy (excluding darunavir) and had HIV-1 RNA less than 200 copies/mL and CD4 count greater than 200 cell/µL for at least 3 months prior to randomization. The safety profile of pitavastatin tablets was generally consistent with that observed in the clinical trials described above. One patient (0.8%) treated with pitavastatin tablets had a peak creatine phosphokinase value exceeding 10 times the upper limit of normal (ULN), which resolved spontaneously. Four patients (3%) treated with pitavastatin tablets had at least one ALT value exceeding 3 times but less than 5 times the ULN, none of which led to drug discontinuation. Virologic failure was reported for four patients (3%) treated with pitavastatin tablets (3%) treated with pitavastatin tablets, defined as a confirmed measurement of HIV-1 RNA exceeding 200 copies/mL that was also more than a 2-fold increase from baseline.

Adverse Reactions in Pediatric Patients Aged 8 Years and Older with HeFH

In a 12-week, double-blind, placebo-controlled trial of pitavastatin tablets 1 mg, 2 mg, and 4 mg once daily in 82 pediatric patients 8 years to 16 years of age with HeFH and a 52-week open-label trial in 85 pediatric patients with HeFH, the safety profile was similar to that observed in the adult population.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of pitavastatin tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal Disorders: abdominal discomfort, abdominal pain, dyspepsia, nausea

General Disorders: asthenia, fatigue, malaise, dizziness

Hepatobiliary Disorders: hepatitis, jaundice, fatal and non-fatal hepatic failure

Immune System Disorders: angioedema, immune-mediated necrotizing myopathy associated with statin use

Metabolism and Nutrition Disorders: increases in HbA1c, fasting serum glucose levels

Musculoskeletal and Connective Tissue Disorders: muscle spasms, myopathy,

rhabdomyolysis

Nervous System Disorders: hypoesthesia, peripheral neuropathy

Psychiatric Disorders: insomnia, depression. Rare reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. Cognitive impairment was generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

Reproductive System and Breast Disorders: erectile dysfunction

Respiratory, Thoracic and Mediastinal Disorders: interstitial lung disease

Skin and Subcutaneous Tissue Disorders: lichen planus

7 DRUG INTERACTIONS

Table 2 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when administered concomitantly with pitavastatin tablets and instructions for preventing or managing drug interactions [see Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].

Cyclosporine							
	Cyclosporine significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.						
Intervention:	Concomitant use of cyclosporine with pitavastatin tablets is contraindicated [see Contraindications (4)].						
Gemfibrozil							
Clinical Impact:	Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with statins, including pitavastatin tablets.						
Intervention:	Avoid concomitant use of gemfibrozil with pitavastatin tablets.						
Erythromycin							
Clinical Impact:	Erythromycin significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.						
Intervention:	In patients taking erythromycin, do not exceed pitavastatin tablets 1 mg once daily [see Dosage and Administration (2.4)].						
Rifampin							
Clinical Impact:	Rifampin significantly increases peak pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.						
Intervention:	In patients taking rifampin, do not exceed pitavastatin tablets 2 mg once daily [see Dosage and Administration (2.4)].						
Fibrates							
Clinical Impact:	Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins, including pitavastatin tablets.						
Intervention:	Consider if the benefit of using fibrates concomitantly with						

Table 2. Drug Interactions that Increase the Risk of Myopathy and
Rhabdomyolysis with Pitavastatin Tablets

	pitavastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis.
Niacin	
Clinical Impact:	The risk of myopathy and rhabdomyolysis may be increased with concomitant use of lipid-modifying doses (≥ 1 g/day) of niacin with pitavastatin tablets.
Intervention:	Consider if the benefit of using lipid-modifying doses (> 1 g/day) of niacin concomitantly with pitavastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis.
Colchicine	
Clinical Impact:	Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with statins, including pitavastatin tablets.
Intervention:	Consider the risk/benefit of concomitant use of colchicine with pitavastatin tablets.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Discontinue pitavastatin tablets when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient.

Pitavastatin tablets decrease synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, pitavastatin tablets may cause fetal harm when administered to pregnant patients based on the mechanism of action *[see Clinical Pharmacology (12.1)]*. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients.

Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with statin use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage (*see Data*).

In animal reproduction studies, no embryo-fetal toxicity or congenital malformations were observed in pregnant rats and rabbits orally administered pitavastatin during the period of organogenesis at doses which were 22 and 4 times, respectively, the human exposure at the maximum recommended human dosage (MRHD) of 4 mg, based on AUC [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Human Data

A Medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was

1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births.

Animal Data

Embryo-fetal developmental studies were conducted in pregnant rats administered 3, 10, 30 mg/kg/day pitavastatin by oral gavage during organogenesis (gestation days 7-17). No adverse effects were observed at 3 mg/kg/day, systemic exposures 22 times human systemic exposure at 4 mg/day based on AUC.

Embryo-fetal developmental studies were conducted in pregnant rabbits administered 0.1, 0.3, 1 mg/kg/day pitavastatin by oral gavage during the period of fetal organogenesis (gestation days 6-18). Maternal toxicity consisting of reduced body weight and abortion was observed at all doses tested (4 times human systemic exposure at 4 mg/day based on AUC).

In perinatal/postnatal studies in pregnant rats given oral gavage doses of pitavastatin at 0.1, 0.3, 1, 3, 10, 30 mg/kg/day from organogenesis through weaning (gestation day 17 to lactation day 21), maternal toxicity consisting of mortality at \geq 0.3 mg/kg/day and impaired lactation at all doses contributed to the decreased survival of neonates in all dose groups (0.1 mg/kg/day represents approximately 1 time human systemic exposure at 4 mg/day dose based on AUC).

Reproductive toxicity studies have shown that pitavastatin crosses the placenta in rats and is found in fetal tissues at \leq 36% of maternal plasma concentrations following a single dose of 1 mg/kg/day during gestation (at the end of organogenesis).

8.2 Lactation

Risk Summary

There is no available information about the presence of pitavastatin in human or animal milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. However, it has been shown that another drug in this class passes into

human milk. Statins, including pitavastatin tablets, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant.

Because of the potential for serious adverse reactions in a breastfed infant, based upon the mechanism of action, advise patients that breastfeeding is not recommended during treatment with pitavastatin tablets. [see Use in Specific Populations (8.1), Clinical Pharmacology (12.1)]

8.4 Pediatric Use

The safety and effectiveness of pitavastatin tablets as an adjunctive therapy to diet to reduce elevated LDL-C in pediatric patients aged 8 years and older with HeFH have been established. Use of pitavastatin tablets for this indication is supported by a 12-week, double-blind, placebo-controlled trial in 82 pediatric patients 8 to 16 years of age with HeFH [see Clinical Studies (14)] and a 52-week open-label trial in 85 pediatric patients with HeFH.

The safety and effectiveness of pitavastatin tablets have not been established in pediatric patients younger than 8 years of age with HeFH or in pediatric patients with other types of hyperlipidemia (other than HeFH).

8.5 Geriatric Use

In controlled clinical studies, 1,209 (43%) patients were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.

Advanced age (\geq 65 years) is a risk factor for pitavastatin tablets-associated myopathy and rhabdomyolysis. Dose selection for a geriatric patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving pitavastatin tablets for the increased risk of myopathy [see Warnings and Precautions (5.1)].

8.6 Renal Impairment

Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. Due to the risk of myopathy, a dosage modification of pitavastatin tablets is recommended for patients with moderate and severe renal impairment (estimated glomerular filtration rate 30–59 mL/min/1.73 m² and 15–29 mL/min/1.73 m², respectively), as well as end-stage renal disease receiving hemodialysis [see Dosage and Administration (2.3), Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].

8.7 Hepatic Impairment

Pitavastatin tablets are contraindicated in patients with active liver failure or decompensated cirrhosis [see Contraindications (4), Warnings and Precautions (5.3)].

10 OVERDOSAGE


No specific treatment for pitavastatin tablets overdose is known. Contact Poison Control

(1-800-222-1222) for latest recommendations. Hemodialysis is unlikely to be of benefit due to high protein binding ratio of pitavastatin tablets.

11 DESCRIPTION

Pitavastatin tablets for oral use are an HMG-CoA reductase inhibitor.

The chemical name for pitavastatin is (+)Monocalcium bis [(3R,5S,6E)-7-[2-cyclopropyl-4-(4- fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate]. The structural formula is:



The molecular formula for pitavastatin is $(C_{25}H_{23}FNO_4)_2$. Ca and the molecular weight is 880.98. Pitavastatin is odorless and occurs as off-white to pale yellow color powder. It is freely soluble in pyridine, chloroform, dilute hydrochloric acid, and tetrahydrofuran, soluble in ethylene glycol, sparingly soluble in octanol, slightly soluble in methanol, very slightly soluble in water or ethanol, and practically insoluble in acetonitrile or diethyl ether. Pitavastatin is hygroscopic and slightly unstable in light.

Each film-coated tablet of pitavastatin contains 1 mg, 2 mg, or 4 mg of pitavastatin, which is equivalent to 1.045 mg, 2.090 mg, or 4.180 mg, respectively, of pitavastatin calcium and the following inactive ingredients: hypromellose, lactose monohydrate, low substituted hydroxypropyl cellulose, magnesium oxide, magnesium stearate, polyethylene glycol, polysorbate 80 and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a ratelimiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very low density lipoproteins.

12.2 Pharmacodynamics

Cardiac Electrophysiology

In a randomized, double-blind, placebo-controlled, 4-way parallel, active-comparator study with moxifloxacin in 174 healthy participants, pitavastatin tablets were not associated with clinically meaningful prolongation of the QTc interval or heart rate at daily doses up to 16 mg (4 times the recommended maximum dose of 4 mg daily).

12.3 Pharmacokinetics

Absorption

Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration. Both C_{max} and AUC_{0-inf} increased in an approximately dose-proportional manner for single pitavastatin tablets doses from 1 mg to 24 mg once daily. The absolute bioavailability of pitavastatin oral solution is 51%. The C_{max} and AUC of pitavastatin did not differ following evening or morning drug administration. In healthy volunteers receiving 4 mg pitavastatin, the percent change from baseline for LDL-C following evening was slightly greater than that following morning dosing. Pitavastatin was absorbed in the small intestine but very little in the colon.

Effect of Food

Administration of pitavastatin tablets with a high fat meal (50% fat content) decreases pitavastatin C_{max} by 43% but does not significantly reduce pitavastatin AUC.

Distribution

Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.

Elimination

Metabolism

The principal route of pitavastatin metabolism is glucuronidation via liver uridine 5'diphosphate glucuronosyltransferase (UGT) with subsequent formation of pitavastatin lactone. There is only minimal metabolism by the cytochrome P450 system. Pitavastatin is marginally metabolized by CYP2C9 and to a lesser extent by CYP2C8. The major metabolite in human plasma is the lactone, which is formed via an ester-type pitavastatin glucuronide conjugate by UGTs (UGT1A3 and UGT2B7).

Excretion

A mean of 15% of radioactivity of orally administered, single 32 mg ¹⁴C-labeled pitavastatin dose was excreted in urine, whereas a mean of 79% of the dose was excreted in feces within 7 days. The mean plasma elimination half-life is approximately 12 hours.

Specific Populations

Geriatric Patients

In a pharmacokinetic study which compared healthy young and geriatric (\geq 65 years) volunteers, pitavastatin C_{max} and AUC were 10 and 30% higher, respectively, in the geriatric patients [see Use in Specific Populations (8.5)].

Pediatric Patients

A 12-week study in pediatric patients 8 to 16 years of age treated with pitavastatin 1 mg, 2 mg and 4 mg administered once daily, showed a dose-dependent increase in pitavastatin plasma concentrations at trough (for 2 mg and 4 mg doses) and 1 hour post dose. A dose-dependent increase in pitavastatin lactone plasma concentrations was observed at trough and 1 hour post dose.

Male and Female Patients

In a pharmacokinetic study, which compared healthy male and female volunteers, pitavastatin C_{max} and AUC were 60 and 54% higher, respectively in females.

Racial or Ethnic Groups

In pharmacokinetic studies pitavastatin C_{max} and AUC were 21 and 5% lower, respectively in Black or African American healthy volunteers compared with those of White healthy volunteers. In pharmacokinetic comparison between White volunteers and Japanese volunteers, there were no significant differences in C_{max} and AUC.

Patients with Renal Impairment

In patients with moderate renal impairment (estimated glomerular filtration rate of 30–59 mL/min/1.73 m²) and end stage renal disease receiving hemodialysis, pitavastatin AUC_{0-inf} is 102% and 86% higher than those of healthy volunteers, respectively, while pitavastatin C_{max} is 60% and 40% higher than those of healthy volunteers, respectively. Patients received hemodialysis immediately before pitavastatin dosing and did not undergo hemodialysis during the pharmacokinetic study. Hemodialysis patients have 33% and 36% increases in the mean unbound fraction of pitavastatin as compared to healthy volunteers and patients with moderate renal impairment, respectively [see Use in Specific Populations (8.6)].

In another pharmacokinetic study, patients with severe renal impairment (estimated glomerular filtration rate 15–29 mL/min/1.73 m²) not receiving hemodialysis were administered a single dose of pitavastatin tablets 4 mg. The AUC_{0-inf} and the C_{max} were 36% and 18% higher, respectively, compared with those of healthy volunteers. For both patients with severe renal impairment and healthy volunteers, the mean percentage of protein-unbound pitavastatin was approximately 0.6% [see Use in Specific Populations (8.6)].

The effect of mild renal impairment on pitavastatin exposure has not been studied.

Patients with Hepatic Impairment

The disposition of pitavastatin was compared in healthy volunteers and patients with various degrees of hepatic impairment. Pitavastatin C_{max} and AUC_{inf} in patients with moderate hepatic impairment (Child-Pugh B disease) was 2.7-fold and 3.8-fold higher, respectively as compared to healthy volunteers. In patients with mild hepatic impairment (Child-Pugh A disease), pitavastatin C_{max} and AUC_{inf} were 30% and 60% higher as compared to healthy volunteers. Mean pitavastatin half-life for moderate hepatic impairment, mild hepatic impairment, and healthy volunteers were 15, 10, and 8 hours, respectively [see Contraindications (4), Warnings and Precautions (5.3)].

Drug Interaction Studies

*Warfarin:*The steady-state pharmacodynamics (international normalized ratio [INR] and prothrombin time [PT]) and pharmacokinetics of warfarin in healthy volunteers were unaffected by the coadministration of pitavastatin tablets 4 mg daily.

Table 3 presents the effect of coadministered drugs on pitavastatin systemic exposure:

Coadministered Drug	Dosage Regimen	Change in AUC*	Change in C _{max} *		
Cyclosporine	Pitavastatin 2 mg QD for 6 days + cyclosporine 2 mg/kg on Day 6	↑ 4.6-fold [†]	↑ 6.6 fold [†]		
Erythromycin	Pitavastatin 4 mg single dose on Day 4 + erythromycin 500 mg 4 times daily for 6 days	↑ 2.8-fold†	↑ 3.6-fold [†]		
Rifampin	Pitavastatin 4 mg QD + rifampin 600 mg QD for 5 days	↑ 29%	↑ 2.0-fold		
Atazanavir	Pitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days	↑ 31%	↑ 60%		
Darunavir/Ritonavir	Pitavastatin 4 mg QD on Days 1-5				
Lopinavir/Ritonavir	Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9-24	↓ 20%	↓ 4%		
Gemfibrozil	Pitavastatin 4 mg QD + gemfibrozil 600 mg BID for 7 days	↑ 45%	↑ 31%		
Fenofibrate	Pitavastatin 4 mg QD + fenofibrate 160 mg QD for 7 days	↑ 18%	↑ 11%		
Ezetimibe	Pitavastatin 2 mg QD + ezetimibe 10 mg for 7 days	↓ 2%	↓ 0.2%		
Enalapril	Pitavastatin 4 mg QD + enalapril 20 mg daily for 5 days	↑ 6%	↓ 7%		
Digoxin	Pitavastatin 4 mg QD + digoxin 0.25 mg for 7 days	↑ 4%	↓ 9%		
Diltiazem LA	Pitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15	↑ 10%	↑ 15%		
Grapefruit Juice	Pitavastatin 2 mg single dose on Day 3 + grapefruit juice for 4 days	↑ 15%	↓ 12%		

Table 3. Effect of Coadministered Drugs on Pitavastatin Systemic Exposure

	Pitavastatin 4 mg single dose on Day		
Itraconazole	4 + itraconazole 200 mg daily for 5 days	↓ 23%	↓ 22%

BID = twice daily; QD = once daily; LA = Long Acting

* Data presented as x-fold change represent the ratio between coadministration and pitavastatin alone (i.e., 1-fold = no change). Data presented as % change represent % difference relative to pitavastatin alone (i.e., 0% = no change).

+ Considered clinically significant [see Dosage and Administration (2.4) and Drug Interactions (7)]

Table 4 presents the effect of pitavastatin coadministration on systemic exposure of other drugs:

Coadministered Drug	Dosage Regi	Change in AUC [*]	Change in C _{max} *				
Atazanavir	Pitavastatin 4 mg QD + 300 mg daily for 5 days	↑ 6%	↑ 13%				
Darunavir	and	Pitavastatin 4 mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800					
Lopinavir	Pitavastatin 4 mg QD or and 20-24 + lopinavir/ritonav mg/100 mg BID on Days 9-24	↓ 9%	↓ 7%				
Ritonavir	and	20-24 + lopinavir/ritonavir 400 mg/100					
Ritonavir	Pitavastatin 4 mg QD or and 12-16 + darunavir/riton mg/100 mg QD on Days 6-16	↑ 8%	↑ 2%				
	Pitavastatin 4 mg QD +	Enalapril	↑ 12%	↑ 12%			
Enalapril	enalapril 20 mg daily for 5 days	Enalaprilat	↓ 1%	↓ 1%			
	Individualized	R-warfarin	↑ 7%	↑ 3%			
Warfarin	maintenance dose of warfarin (2-7 mg) for 8 days + pitavastatin 4 mg	S-warfarin	↑ 6%	↑ 3%			

Table 4. Effect of Pitavastatin Coadministration on Systemic Exposure toOther Drugs

	QD for 9 days		
Ezetimibe	Pitavastatin 2 mg QD + ezetimibe 10 mg for 7 days	↑ 9%	↑ 2%
Digoxin	Pitavastatin 4 mg QD + digoxin 0.25 mg for 7 days	↓ 3%	↓ 4%
Diltiazem LA	Pitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15	↓ 2%	↓ 7%
Rifampin	Pitavastatin 4 mg QD + rifampin 600 mg QD for 5 days	↓ 15%	↓ 18%

BID = twice daily; QD = once daily; LA = Long Acting

 * Data presented as % change represent % difference relative to the investigated drug alone (i.e., 0% = no change).

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 92-week carcinogenicity study in mice given pitavastatin, at the maximum tolerated dose of 75 mg/kg/day with systemic maximum exposures (AUC) 26 times the clinical maximum exposure at 4 mg daily, there was an absence of drug-related tumors.

In a 92-week carcinogenicity study in rats given pitavastatin at 1, 5, 25 mg/kg/day by oral gavage there was a significant increase in the incidence of thyroid follicular cell tumors at 25 mg/kg/day, which represents 295 times human systemic exposures based on AUC at the 4 mg daily maximum human dose.

In a 26-week transgenic mouse (Tg rasH2) carcinogenicity study where animals were given pitavastatin at 30, 75, and 150 mg/kg/day by oral gavage, no clinically significant tumors were observed.

Pitavastatin was not mutagenic in the Ames test with *Salmonella typhimurium* and *Escherichia coli* with and without metabolic activation, the micronucleus test following a single administration in mice and multiple administrations in rats, the unscheduled DNA synthesis test in rats, and a Comet assay in mice. In the chromosomal aberration test, clastogenicity was observed at the highest doses tested, which also elicited high levels of cytotoxicity.

Pitavastatin had no adverse effects on male and female rat fertility at oral doses of 10 and 30 mg/kg/day, respectively, at systemic exposures 56- and 354-times clinical exposure at 4 mg daily based on AUC.

Pitavastatin treatment in rabbits resulted in mortality in males and females given 1 mg/kg/day (30-times clinical systemic exposure at 4 mg daily based on AUC) and higher during a fertility study. Although the cause of death was not determined, rabbits had gross signs of renal toxicity (kidneys whitened) indicative of possible ischemia. Lower doses (15-times human systemic exposure) did not show significant toxicity in adult males and females. However, decreased implantations, increased resorptions, and

decreased viability of fetuses were observed.

14 CLINICAL STUDIES

Primary Hyperlipidemia in Adults: Study with Atorvastatin (Study

301): Pitavastatin tablets were compared with atorvastatin calcium tablets (referred to as atorvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 817 adult patients with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period and then were randomized to a 12-week treatment with either pitavastatin tablets or atorvastatin (Table 5). Non-inferiority of pitavastatin to a given dose of atorvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C.

Lipid results are shown in Table 5. For the percent change from baseline to endpoint in LDL-C, pitavastatin tablets were non-inferior to atorvastatin for the two pairwise comparisons: pitavastatin tablets 2 mg vs. atorvastatin 10 mg and pitavastatin tablets 4 mg vs. atorvastatin 20 mg. Mean treatment differences (95% CI) were 0% (-3%, 3%) and 1% (-2%, 4%), respectively.

Treatment	Ν	LDL-C	Аро-В	ТС	TG	HDL-C	non-HDL-C
Pitavastatin Tablets 2 mg daily	315	-38	-30	-28	-14	4	-35
Pitavastatin Tablets 4 mg daily	298	-45	-35	-32	-19	5	-41
Atorvastatin 10 mg daily	102	-38	-29	-28	-18	3	-35
Atorvastatin 20 mg daily	102	-44	-36	-33	-22	2	-41

Table 5. Lipid Response by Dose of Pitavastatin Tablets and Atorvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study 301 (Mean % Change from Baseline at Week 12)

Study with Simvastatin (Study 302): Pitavastatin tablets were compared with simvastatin tablets (referred to as simvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 843 adult patients with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period and then were randomized to a 12 week treatment with either pitavastatin tablets or simvastatin (Table 6). Non-inferiority of pitavastatin to a given dose of simvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C.

Lipid results are shown in Table 6. For the percent change from baseline to endpoint in LDL-C, pitavastatin tablets were non-inferior to simvastatin for the two pairwise comparisons: pitavastatin tablets 2 mg vs. simvastatin 20 mg and pitavastatin tablets 4 mg vs. simvastatin 40 mg. Mean treatment differences (95% CI) were 4% (1%, 7%) and

Treatment	Ν	LDL-C	Аро-В	ТС	TG	HDL-C	non-HDL-C
Pitavastatin Tablets 2 mg daily	307	-39	-30	-28	-16	6	-36
Pitavastatin Tablets 4 mg daily	319	-44	-35	-32	-17	6	-41
Simvastatin 20 mg daily	107	-35	-27	-25	-16	6	-32
Simvastatin 40 mg daily	110	-43	-34	-31	-16	7	-39

Table 6. Lipid Response by Dose of Pitavastatin Tablets and Simvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study 302 (Mean % Change from Baseline at Week 12)

Study with Pravastatin in Geriatric Patients (Study 306): Pitavastatin tablets were compared with pravastatin sodium tablets (referred to as pravastatin) in a randomized, multicenter, double-blind, double-dummy, parallel group, active-controlled non-inferiority study of 942 geriatric patients (\geq 65 years) with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period, and then were randomized to a once daily dose of pitavastatin tablets or pravastatin for 12 weeks (Table 7). Non-inferiority of pitavastatin tablets to a given dose of pravastatin was assumed if the lower bound of the 95% CI for the treatment difference was greater than -6% for the mean percent change in LDL-C.

Lipid results are shown in Table 7. Pitavastatin tablets significantly reduced LDL-C compared to pravastatin as demonstrated by the following pairwise dose comparisons: pitavastatin tablets 1 mg vs. pravastatin 10 mg, pitavastatin tablets 2 mg vs. pravastatin 20 mg and pitavastatin tablets 4 mg vs. pravastatin 40 mg. Mean treatment differences (95% CI) were 9% (6%, 12%), 10% (7%, 13%) and 10% (7%, 13%), respectively.

Table 7. Lipid Response by Dose of Pitavastatin Tablets and Pravastatin in
Geriatric Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study
306 (Mean % Change from Baseline at Week 12)

Treatment	Ν	LDL-C	Аро-В	ТС	TG	HDL-C	non-HDL-C
Pitavastatin Tablets 1 mg daily	207	-31	-25	-22	-13	1	-29
Pitavastatin Tablets 2 mg daily	224	-39	-31	-27	-15	2	-36
Pitavastatin Tablets 4 mg daily	210	-44	-37	-31	-22	4	-41
Pravastatin 10 mg daily	103	-22	-17	-15	-5	0	-20
Pravastatin 20 mg daily	96	-29	-22	-21	-11	-1	-27

Pravastatin 102 -34 -28 -24 -15 1 -32	Pravastatin 40 mg daily		12 - 34	-/8			1	-32
---	----------------------------	--	---------	-----	--	--	---	-----

Study with Simvastatin in Patients with ≥ 2 Risk Factors for Coronary Heart Disease (Study 304): Pitavastatin tablets were compared with simvastatin tablets (referred to as simvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 351 adult patients with primary hyperlipidemia or mixed dyslipidemia with ≥ 2 risk factors for coronary heart disease. After a 6- to 8week wash-out/dietary lead-in period, patients were randomized to a 12-week treatment with either pitavastatin tablets or simvastatin (Table 8). Non-inferiority of pitavastatin tablets to simvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C.

Lipid results are shown in Table 8. Pitavastatin tablets 4 mg were non-inferior to simvastatin 40 mg for percent change from baseline to endpoint in LDL-C. The mean treatment difference (95% CI) was 0% (-2%, 3%).

Table 8. Lipid Response by Dose of Pitavastatin Tablets and Simvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia with ≥ 2 Risk Factors for Coronary Heart Disease in Study 304 (Mean % Change from Baseline at Week 12)

Treatment	Ν	LDL-C	Аро-В	ТС	TG	HDL-C	non-HDL-C
Pitavastatin Tablets 4 mg daily	233	-44	-34	-31	-20	7	-40
Simvastatin 40 mg daily	118	-44	-34	-31	-15	5	-39

Study with Atorvastatin in Patients with Type 2 Diabetes Mellitus (Study 305): Pitavastatin tablets were compared with atorvastatin calcium tablets (referred to as atorvastatin) in a randomized, multicenter, double blind, double dummy, parallel


as atorvastatin) in a randomized, multicenter, double-blind, double-dummy, parallel group, active-controlled, non-inferiority study of 410 adult patients with type 2 diabetes mellitus and mixed dyslipidemia. Patients entered a 6- to 8-week washout/dietary lead-in period and were randomized to a once daily dose of pitavastatin tablets or atorvastatin for 12 weeks. Non-inferiority of pitavastatin tablets was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C.

Lipid results are shown in Table 9. The treatment difference (95% CI) for LDL-C percent change from baseline was -2% (-6.2%, 1.5%). The two treatment groups were not statistically different on LDL-C. However, the lower limit of the CI was -6.2%, slightly exceeding the -6% non-inferiority limit. The study failed to demonstrate that pitavastatin tablets were not significantly different than atorvastatin in lowering LDL-C in patients with type 2 diabetes mellitus and mixed dyslipidemia.

Table 9. Lipid Response by Dose of Pitavastatin Tablets and Atorvastatin in Adult Patients with Type 2 Diabetes Mellitus and Mixed Dyslipidemia in Study 305 (Mean % Change from Baseline at Week 12)

Treatment	Ν	LDL-C	Аро-В	ТС	TG	HDL-C	non-HDL-C
Pitavastatin Tablets 4 mg daily	274	-41	-32	-28	-20	7	-36
Atorvastatin 20 mg daily	136	-43	-34	-32	-27	8	-40

The treatment differences in efficacy in LDL-C change from baseline between pitavastatin tablets and active controls (i.e., atorvastatin, simvastatin, or pravastatin) in the active-controlled studies described above are summarized in Figure 1.



NL = non-inferiority limit.

Figure 1. Treatment Difference in Adjusted Mean Percent Change in LDL-C between Pitavastatin Tablets and the Comparator (Atorvastatin, Simvastatin, or Pravastatin)

HeFH in Pediatric Patients: In a double-blind, placebo-controlled, 12-week trial, 82 pediatric patients (36 boys and 46 girls), 8 to 16 years of age with genetically confirmed

HeFH, fasting low-density lipoprotein cholesterol (LDL-C) \geq 190 mg/dL or LDL-C \geq 160 mg/dL with an additional cardiovascular risk factor (male gender, a family history of premature CV disease, presence of low HDL (< 45 mg/dL) or high TG (> 150 mg/dL), presence of high lipoprotein (a) (> 75 nmol/L), presence of type 2 diabetes mellitus or presence of hypertension) were randomized to pitavastatin tablets 1 mg, 2 mg, and 4 mg. Mean LDL-C at baseline was 235 mg/dL (range 160.5 mg/dL to 441 mg/dL). Approximately 39% of patients were Tanner Stage 1 at baseline.

Pitavastatin tablets significantly reduced plasma LDL-C, non-HDL-C, TC, and Apo-B compared to placebo. The reductions in LDL-C, Apo-B, TC, and non-HDL-C were dose dependent. There was no statistically significant improvement in HDL-C or TG at any pitavastatin tablets dose. See the lipid results in Table 10.

Treatment	Ν	LDL-C	Apo-B	ТС	TG*†	HDL-C*	non-HDL-C
Placebo	19	-1	-3	-1	-3	-1	-1
Pitavastatin Tablets 1 mg daily	20	-21	-20	-16	-14	7	-21
Pitavastatin Tablets 2 mg daily	24	-30	-25	-25	-15	-3	-29
Pitavastatin Tablets 4 mg daily	19	-38	-28	-30	5	-2	-36

Table 10. Lipid Response in Pediatric Patients with HeFH (Mean % Change
from Baseline at Week 12)

* Difference from placebo not statistically significant

† Median Percent Change from Baseline at Week 12

16 HOW SUPPLIED/STORAGE AND HANDLING

Pitavastatin Tablets are available containing 1.045 mg, 2.090 mg or 4.180 mg of pitavastatin calcium equivalent to 1 mg, 2 mg or 4 mg of pitavastatin, respectively.

The 1 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **PU1** on the other side. They are available as follows:

NDC-0378-5055-93 bottles of 30 tablets

NDC-0378-5055-77 bottles of 90 tablets

NDC-0378-5055-05 bottles of 500 tablets

The 2 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **PU2** on the other side. They are available as follows:

NDC-0378-5056-93

bottles of 30 tablets

NDC-0378-5056-77 bottles of 90 tablets

NDC-0378-5056-05 bottles of 500 tablets

The 4 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **PU4** on the other side. They are available as follows:

NDC-0378-5057-93 bottles of 30 tablets

NDC-0378-5057-77 bottles of 90 tablets

NDC-0378-5057-05 bottles of 500 tablets

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Protect from moisture and light.

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

17 PATIENT COUNSELING INFORMATION

Myopathy and Rhabdomyolysis: Advise patients that pitavastatin tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [see Warnings and Precautions (5.1)].

Hepatic Dysfunction: Inform patients that pitavastatin tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice [see Warnings and Precautions (5.3)].

Increases in HbA1c and Fasting Serum Glucose Levels: Inform patients that increases in HbA1c and fasting serum glucose levels may occur with pitavastatin tablets. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices [see Warnings and *Precautions (5.4)*].

Pregnancy: Advise pregnant patients and patients who become pregnant of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if pitavastatin tablets should be discontinued [see Use in Specific Populations (8.1)].

Lactation: Advise patients that breastfeeding is not recommended during treatment with pitavastatin tablets [see Use in Specific Populations (8.2)].

Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Manufactured by: **Mylan Laboratories Limited** Hyderabad—500 096, India

75056706

Revised: 2/2023 MX:PITA:R3

PRINCIPAL DISPLAY PANEL - 1 mg

NDC 0378-5055-93

Pitavastatin Tablets 1 mg

Rx only 30 Tablets

Each film-coated tablet contains 1.045 mg of pitavastatin calcium equivalent to 1 mg of pitavastatin.

Usual Dosage: See accompanying prescribing information.

Keep this and all medication out of the reach of children.

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Protect from moisture and light.

Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Made in India

Mylan.com

RMX5055H1

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Keep container tightly closed.

Code No.: MH/DRUGS/25/NKD/89



PRINCIPAL DISPLAY PANEL - 2 mg

NDC 0378-5056-93

Pitavastatin Tablets

2 mg

Rx only 30 Tablets

Each film-coated tablet contains 2.090 mg of pitavastatin calcium equivalent to 2 mg of pitavastatin.

Usual Dosage: See accompanying prescribing information.

Keep this and all medication out of the reach of children.

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Protect from moisture and light.

Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Made in India

Mylan.com

RMX5056H1

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Keep container tightly closed.



PRINCIPAL DISPLAY PANEL - 4 mg

NDC 0378-5057-93

Pitavastatin Tablets 4 mg

Rx only 30 Tablets

Each film-coated tablet contains 4.180 mg of pitavastatin calcium equivalent to 4 mg of pitavastatin.

Usual Dosage: See accompanying prescribing information.

Keep this and all medication out of the reach of children.

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Protect from moisture and light.

Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Made in India

Mylan.com

RMX5057H1

Dispense in a tight, light-resistant container as defined in the USP

using a child-resistant closure.

Keep container tightly closed.

Code No.: MH/DRUGS/25/NKD/89



PITAVASTATIN CALC	CIUM				
pitavastatin tablet, film coated	k				
•					
Product Information					
		H C	(6)		
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code	(Source)	NDC:03	378-5055
Route of Administration	ORAL				
Active Ingredient/Active	Moiety				
Ing	redient Name		Basis of Stre	ength	Strength
PITAVASTATIN CALCIUM (UNII: IN	D54XEG3W) (PITAVASTATIN - UNII:M	5681Q5F9P)	PITAVASTATIN		1 mg
Inactive Ingredients					
	Ingredient Name			1	Strength
HYPROMELLOSE, UNSPECIFIED	(UNII: 3NXW29V3WO)				
LACTOSE MONOHYDRATE (UNII:	EWQ57Q8I5X)				
LOW-SUBSTITUTED HYDROXYP	ROPYL CELLULOSE, UNSPECIFIE	D (UNII: 2165	RE0K14)		
MAGNESIUM OXIDE (UNII: 3A3U0	GI71G)				
MAGNESIUM STEARATE (UNII: 70	097M6I30)				
POLYETHYLENE GLYCOL 400 (U	NII: B697894SGQ)				
POLYSORBATE 80 (UNII: 60ZP39	ZG8H)				
TITANIUM DIOXIDE (UNII: 15FIX9)	/2JP)				
Product Characteristics					
Color WHITE (white	e to off-white)	Score		no so	core

Sł	аре	ROUND	Size	5mm
Fla	avor		Imprint Code	M;PU1
Co	ontains			
D	ackaging			
Г			Marketing Start	Marketing End
#	Item Code	Package Description	Date	Date
1	NDC:0378- 5055-93	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	01/01/2030	
2	NDC:0378- 5055-77	90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	11/02/2023	
3	NDC:0378- 5055-05	500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	01/01/2030	
Μ	arketing	Information		
	Marketing Category	Application Number or Monogra Citation	aph Marketing Start Date	Marketing End Date
	DA	ANDA206070	11/02/2023	

PITAVASTATIN CALC	IUM				
pitavastatin tablet, film coated	l i i i i i i i i i i i i i i i i i i i				
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code	(Source)	NDC:0	378-5056
Route of Administration	ORAL				
Active Ingredient/Active	Moiety				
Ingi	redient Name		Basis of Stre	ength	Strength
PITAVASTATIN CALCIUM (UNII: IY	D54XEG3W) (PITAVASTATIN - UNII:M	5681Q5F9P)	PITAVASTATIN		2 mg
Inactive Ingredients					
	Ingredient Name				Strength
HYPROMELLOSE, UNSPECIFIED	(UNII: 3NXW29V3WO)				
LACTOSE MONOHYDRATE (UNII:					
LOW-SUBSTITUTED HYDROXYP		D (UNII: 2165	RE0K14)		
MAGNESIUM OXIDE (UNII: 3A3U00	·				
MAGNESIUM STEARATE (UNII: 700	•				
POLYETHYLENE GLYCOL 400 (UI					
POLYSORBATE 80 (UNII: 60ZP392					
TITANIUM DIOXIDE (UNII: 15FIX9V	⁽² JP)				
Product Characteristics					
Product Characteristics					

Color	WHITE (white to off-white)	Score	no score
Shape	ROUND	Size	7mm
Flavor		Imprint Code	M;PU2
Contains			

-		
Pac	Van	ind
r au	Ngu	шч

#	ltem Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0378- 5056-93	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	01/01/2030	
2	NDC:0378- 5056-77	90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	11/02/2023	
3	NDC:0378- 5056-05	500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	01/01/2030	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA206070	11/02/2023	
ANDA	ANDA206070	11/02/2023	

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC	PITAVASTATIN CALC	UUM			
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:378-5057 Route of Administration ORAL ORAL Strength Active Ingredient/Active Woiety Strength Strength PITAVASTATIN CALCIUM (UNII: IYD54XEG3W) (PITAVASTATIN - UNII:M559P) PITAVASTATIN CALCIUM (UNII: STRATGRAGE) 4 mg Inactive Ingredients Strength 4 mg Inactive Ingredients Strength 5 Strength HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) Strength 4 mg Lactose MONOHYDRATE (UNII: SUSTQ8ISX) Strength 5 Strength IOW-SUBSTITUTED HYDROXYFVPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14) I 1 Magnesium STEARATE (UNII: 303U0G171G) I I I Magnesium STEARATE (UNII: 303U0G171G) I I I POLYSORBATE 80 (UNII: 602P39ZG8H) I I I	pitavastatin tablet, film coatec	ł			
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:378-5057 Route of Administration ORAL ORAL Strength Active Ingredient/Active Woiety Strength Strength PITAVASTATIN CALCIUM (UNII: IYD54XEG3W) (PITAVASTATIN - UNII:M559P) PITAVASTATIN CALCIUM (UNII: STRATGRAGE) 4 mg Inactive Ingredients Strength 4 mg Inactive Ingredients Strength 5 Strength HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) Strength 4 mg Lactose MONOHYDRATE (UNII: SUSTQ8ISX) Strength 5 Strength IOW-SUBSTITUTED HYDROXYFVPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14) I 1 Magnesium STEARATE (UNII: 303U0G171G) I I I Magnesium STEARATE (UNII: 303U0G171G) I I I POLYSORBATE 80 (UNII: 602P39ZG8H) I I I					
Route of Administration ORAL Active Ingredient/Active Moiety Basis of Strength Ingredient Name Basis of Strength PITAVASTATIN CALCIUM (UNII: IYD54XEG3W) (PITAVASTATIN - UNII:M5681Q5F9P) PITAVASTATIN Inactive Ingredients 4 mg Inactive Ingredients 5 trength HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) 5 trength LACTOSE MONOHYDRATE (UNII: EWQ57Q8ISX) 5 trength IOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14) 5 trength MAGNESIUM OXIDE (UNII: 3A3U0GI71G) 5 trength MAGNESIUM STEARATE (UNII: 70097M6130) 5 trength POLYSORBATE 80 (UNII: 60ZP39ZG8H) 5 trength	Product Information				
Active Ingredient/Active Moiety Basis of Strength Strength PITAVASTATIN CALCIUM (UNII: IYD54XEG3W) (PITAVASTATIN - UNII:M5681Q5F9P) PITAVASTATIN 4 mg Inactive Ingredients VITAVASTATIN 4 mg Inactive Ingredients Strength Ingredient Name Strength HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) VITAVASTATIN LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) VITAVASTATIN LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14) VITAVASTATIN MAGNESIUM OXIDE (UNII: 3A3U0GI71G) VITAVASTATIN MAGNESIUM STEARATE (UNII: 70097M6I30) VITAVASTATIN POLYSORBATE 80 (UNII: 60ZP39ZG8H) VITAVASTATIN	Product Type	HUMAN PRESCRIPTION DRUG	ltem Code	(Source)	NDC:0378-5057
Ingredient NameBasis of StrengthPITAVASTATIN CALCIUM (UNII: IYD54XEG3W) (PITAVASTATIN - UNII:M5681Q5F9P)PITAVASTATIN4 mgInactive IngredientsVVVInactive IngredientsStrengthStrengthHYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)StrengthStrengthLACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)StrengthStrengthLOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165E0K14)StrengthMAGNESIUM OXIDE (UNII: 3A3U0G171G)StrengthStrengthPOLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)StrengthStrengthPOLYSORBATE 80 (UNII: 60ZP39ZG8H)StrengthStrength	Route of Administration	ORAL			
Ingredient NameBasis of StrengthStrengthPITAVASTATIN CALCIUM (UNII: IYD54XEG3W) (PITAVASTATIN - UNII:M5681Q5F9P)PITAVASTATIN4 mgInactive IngredientsVariableStrengthInactive IngredientsStrengthHYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)StrengthLACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)StrengthLOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165E0K14)StrengthMAGNESIUM OXIDE (UNII: 3A3U0G171G)StrengthPOLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)StrengthPOLYSORBATE 80 (UNII: 60ZP39ZG8H)Strength					
Ingredient NameBasis of StrengthPITAVASTATIN CALCIUM (UNII: IYD54XEG3W) (PITAVASTATIN - UNII:M5681Q5F9P)PITAVASTATIN4 mgInactive IngredientsVVVInactive IngredientsStrengthStrengthHYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)StrengthStrengthLACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)StrengthStrengthLOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165E0K14)StrengthMAGNESIUM OXIDE (UNII: 3A3U0G171G)StrengthStrengthPOLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)StrengthStrengthPOLYSORBATE 80 (UNII: 60ZP39ZG8H)StrengthStrength					
PITAVASTATIN CALCIUM (UNII: IYD54XEG3W) (PITAVASTATIN - UNII:M5681Q5F9P) PITAVASTATIN 4 mg Inactive Ingredients Ingredient Name Strength HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14) MAGNESIUM OXIDE (UNII: 3A3U0GI71G) MAGNESIUM STEARATE (UNII: 70097M6I30) POLYETHYLENE GLYCOL 400 (UNII: B6978945GQ) POLYSORBATE 80 (UNII: 60ZP39ZG8H) 4 mg	Active Ingredient/Active	Moiety			
Inactive IngredientsStrengthIngredient NameStrengthHYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)CLACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)CLOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14)CMAGNESIUM OXIDE (UNII: 3A3U0GI71G)CMAGNESIUM STEARATE (UNII: 70097M6I30)CPOLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)CPOLYSORBATE 80 (UNII: 60ZP39ZG8H)C	Ing	redient Name		Basis of Stre	ength Streng
Ingredient NameStrengthHYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14)MAGNESIUM OXIDE (UNII: 3A3U0GI71G)MAGNESIUM STEARATE (UNII: 70097M6I30)POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)POLYSORBATE 80 (UNII: 60ZP39ZG8H)	PITAVASTATIN CALCIUM (UNII: IY	D54XEG3W) (PITAVASTATIN - UNII:M	5681Q5F9P)	PITAVASTATIN	4 mg
Ingredient NameStrengthHYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14)MAGNESIUM OXIDE (UNII: 3A3U0GI71G)MAGNESIUM STEARATE (UNII: 70097M6I30)POLYETHYLENE GLYCOL 400 (UNII: 8697894SGQ)POLYSORBATE 80 (UNII: 60ZP39ZG8H)					
HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)Image: Constant of the co	Inactive Ingredients				
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)ContemporalLOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14)ContemporalMAGNESIUM OXIDE (UNII: 3A3U0GI71G)ContemporalMAGNESIUM STEARATE (UNII: 70097M6I30)ContemporalPOLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)ContemporalPOLYSORBATE 80 (UNII: 60ZP39ZG8H)Contemporal		Ingredient Name			Strengt
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14) MAGNESIUM OXIDE (UNII: 3A3U0GI71G) MAGNESIUM STEARATE (UNII: 70097M6I30) POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) POLYSORBATE 80 (UNII: 60ZP39ZG8H)	HYPROMELLOSE, UNSPECIEIED				
MAGNESIUM OXIDE (UNII: 3A3U0GI71G) MAGNESIUM STEARATE (UNII: 70097M6I30) POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) POLYSORBATE 80 (UNII: 60ZP39ZG8H)		(UNII: 3NXW29V3WO)			
MAGNESIUM STEARATE (UNII: 70097M6I30) POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) POLYSORBATE 80 (UNII: 60ZP39ZG8H)					
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) POLYSORBATE 80 (UNII: 60ZP39ZG8H)	LACTOSE MONOHYDRATE (UNII:	EWQ57Q8I5X)	D (UNII: 2165	RE0K14)	
POLYSORBATE 80 (UNII: 60ZP39ZG8H)	LACTOSE MONOHYDRATE (UNII: LOW-SUBSTITUTED HYDROXYP	EWQ57Q8I5X) ROPYL CELLULOSE, UNSPECIFIE	d (UNII: 2165	RE0K14)	
	LACTOSE MONOHYDRATE (UNII: LOW-SUBSTITUTED HYDROXYP MAGNESIUM OXIDE (UNII: 3A3U00	EWQ57Q8I5X) ROPYL CELLULOSE, UNSPECIFIE GI71G)	d (UNII: 2165	RE0K14)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	LACTOSE MONOHYDRATE (UNII: LOW-SUBSTITUTED HYDROXYP MAGNESIUM OXIDE (UNII: 3A3U00 MAGNESIUM STEARATE (UNII: 70	EWQ57Q8I5X) ROPYL CELLULOSE, UNSPECIFIE GI71G) 097M6I30)	D (UNII: 2165	RE0K14)	
	LACTOSE MONOHYDRATE (UNII: LOW-SUBSTITUTED HYDROXYP MAGNESIUM OXIDE (UNII: 3A3U00 MAGNESIUM STEARATE (UNII: 70 POLYETHYLENE GLYCOL 400 (U	EWQ57Q8I5X) ROPYL CELLULOSE, UNSPECIFIE GI71G) 097M6I30) NII: B697894SGQ)	D (UNII: 2165	RE0K14)	
	LACTOSE MONOHYDRATE (UNII: LOW-SUBSTITUTED HYDROXYP MAGNESIUM OXIDE (UNII: 3A3U00 MAGNESIUM STEARATE (UNII: 70 POLYETHYLENE GLYCOL 400 (U POLYSORBATE 80 (UNII: 60ZP39	EWQ57Q8I5X) ROPYL CELLULOSE, UNSPECIFIE GI71G) 097M6I30) NII: B697894SGQ) ZG8H)	D (UNII: 2165	RE0K14)	

Product Characteristics						
Color	WHITE (white to off-white)	Score	no score			
Shape	ROUND	Size	7mm			
Flavor		Imprint Code	M;PU4			
Contains						

Packaging					
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:0378- 5057-93	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	01/01/2030		
2	NDC:0378- 5057-77	90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	11/02/2023		
3	NDC:0378- 5057-05	500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	01/01/2030		

Marketing Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
ANDA	ANDA206070	11/02/2023			

Labeler - Mylan Pharmaceuticals Inc. (059295980)

Revised: 2/2023

Mylan Pharmaceuticals Inc.